Cohen Lawrence B purchased a new position in AC Immune SA (NASDAQ:ACIU) during the second quarter, according to its most recent disclosure with the SEC. The fund purchased 33,750 shares of the company’s stock, valued at approximately $297,000. Cohen Lawrence B owned about 0.06% of AC Immune SA as of its most recent filing with the SEC.
Separately, Victory Capital Management Inc. increased its position in shares of AC Immune SA by 78.4% in the first quarter. Victory Capital Management Inc. now owns 26,757 shares of the company’s stock valued at $277,000 after buying an additional 11,757 shares during the period. 18.47% of the stock is owned by hedge funds and other institutional investors.
AC Immune SA (ACIU) opened at 7.12 on Friday. AC Immune SA has a 52 week low of $6.03 and a 52 week high of $19.97. The stock’s market capitalization is $405.28 million. The firm has a 50 day moving average price of $8.14 and a 200 day moving average price of $9.93.
AC Immune SA (NASDAQ:ACIU) last posted its earnings results on Thursday, May 11th. The company reported ($0.17) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.17). The company had revenue of $1.99 million for the quarter, compared to the consensus estimate of $3.43 million. Equities research analysts predict that AC Immune SA will post ($0.63) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Cohen Lawrence B Acquires New Position in AC Immune SA (ACIU)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/08/12/cohen-lawrence-b-takes-position-in-ac-immune-sa-aciu-updated-updated.html.
Several research analysts have weighed in on the company. Zacks Investment Research downgraded AC Immune SA from a “buy” rating to a “hold” rating in a research note on Friday, May 26th. Credit Suisse Group set a $18.00 target price on AC Immune SA and gave the company a “buy” rating in a research note on Wednesday, July 19th.
AC Immune SA Company Profile
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
What are top analysts saying about AC Immune SA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AC Immune SA and related companies.